Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist,” such a compound would appear to have potential as a treatment for scleroderma.
){kind=link}
Comments
Comments are disabled for this post.